Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (41-50 of 176) with videos related to

Pageof 18
Sort By:
Clinical Genitourinary Cancer|November 15, 2013
The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry databaseUlka Vaishampayan, Hema Vankayala, Fawn D Vigneau, et al.
Research Square|March 3, 2023
Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growthBarani Govindarajan, Diego Sbrissa, Mark Pressprich, et al.
Investigational New Drugs|October 31, 2003
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancerMaha Hussain, Ulka Vaishampayan, Lance K Heilbrun, et al.
Anti-Cancer Drugs|July 30, 2011
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunctionSachin Gupta, Venkata Parsa, Lance K Heilbrun, et al.
Expert Review of Anticancer Therapy|November 15, 2013
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-TDavid I Quinn, Ulka Vaishampayan, Celestia S Higano, et al.
European Urology Focus|May 20, 2019
Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaHyung L Kim, Eddie Mayerson, Primo N Lara, et al.
Investigational New Drugs|July 8, 2010
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort studyPatricia Lorusso, Anthony F Shields, Shirish Gadgeel, et al.
American Journal of Translational Research|August 25, 2010
A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancerElisabeth I Heath, Lance K Heilbrun, Jing Li, et al.
Clinical Genitourinary Cancer|April 8, 2016
Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate CancerDipenkumar Modi, Clara Hwang, Hirva Mamdani, et al.
Urology|August 12, 2008
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinomaShanthi Marur, James Eliason, Lance K Heilbrun, et al.
Pageof 18

Showing results (41-50 of 176) with videos related to

Sort By:
Pageof 18
Clinical Genitourinary Cancer|November 15, 2013
The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry databaseUlka Vaishampayan, Hema Vankayala, Fawn D Vigneau, et al.
Research Square|March 3, 2023
Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growthBarani Govindarajan, Diego Sbrissa, Mark Pressprich, et al.
Investigational New Drugs|October 31, 2003
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancerMaha Hussain, Ulka Vaishampayan, Lance K Heilbrun, et al.
Anti-Cancer Drugs|July 30, 2011
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunctionSachin Gupta, Venkata Parsa, Lance K Heilbrun, et al.
Expert Review of Anticancer Therapy|November 15, 2013
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-TDavid I Quinn, Ulka Vaishampayan, Celestia S Higano, et al.
European Urology Focus|May 20, 2019
Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaHyung L Kim, Eddie Mayerson, Primo N Lara, et al.
Investigational New Drugs|July 8, 2010
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort studyPatricia Lorusso, Anthony F Shields, Shirish Gadgeel, et al.
American Journal of Translational Research|August 25, 2010
A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancerElisabeth I Heath, Lance K Heilbrun, Jing Li, et al.
Clinical Genitourinary Cancer|April 8, 2016
Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate CancerDipenkumar Modi, Clara Hwang, Hirva Mamdani, et al.
Urology|August 12, 2008
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinomaShanthi Marur, James Eliason, Lance K Heilbrun, et al.
Pageof 18